Mounjaro vs Ozempic: What’s the Difference?

Mounjaro and Ozempic are two injectable medicines frequently discussed in diabetes care and medical weight management. They are sometimes grouped together because both affect hormone pathways involved in appetite, blood sugar and digestion, but they are not the same medicine.

Mounjaro contains tirzepatide, while Ozempic contains semaglutide. The biggest biological difference is that semaglutide acts on the GLP-1 receptor, while tirzepatide acts on both GIP and GLP-1 receptors.

Mounjaro vs Ozempic at a Glance

What Is Mounjaro?

Mounjaro is a brand of tirzepatide. Tirzepatide activates two hormone receptors: GIP and GLP-1. These pathways are involved in glucose regulation, insulin response, appetite and digestion.

Because it acts on two receptor systems rather than one, tirzepatide is often described as a dual GIP/GLP-1 receptor agonist.

The Thai FDA drug database lists registered Mounjaro products containing tirzepatide in multiple strengths, including pre-filled KwikPen presentations. Registration does not mean that every strength is always in stock or suitable for every patient.

Learn more about Mounjaro (Tirzepatide) in Thailand →

What Is Ozempic?

Ozempic is a brand of semaglutide. Semaglutide is a GLP-1 receptor agonist. It mimics part of the activity of the naturally occurring GLP-1 hormone and can influence insulin secretion, appetite and gastric emptying.

It is important not to treat the words “Ozempic” and “semaglutide” as interchangeable in every context. Semaglutide is the active compound, while Ozempic is one specific branded medicine. Wegovy is another semaglutide-based product with its own approved use and dosing framework depending on jurisdiction.

The Thai FDA drug database lists registered Ozempic pre-filled pen products containing semaglutide in several dose strengths.

Learn more about Ozempic (Semaglutide) in Thailand →

How Do Their Mechanisms Differ?

Which Produces More Weight Loss?

There is now direct clinical-trial evidence comparing tirzepatide with semaglutide in adults with obesity. In a 72-week randomized trial published in the New England Journal of Medicine, average body-weight reduction was greater with tirzepatide than with semaglutide: approximately 20.2% versus 13.7% in the trial populations.

That result is useful evidence, but it does not mean that every individual will lose that amount of weight or that tirzepatide is automatically the correct choice for every patient. Trial participants are selected according to study criteria, treatment is titrated and monitored, and individual responses vary substantially.

An earlier head-to-head trial in people with type 2 diabetes also found greater average weight reductions with tirzepatide than semaglutide 1 mg over 40 weeks.

Are Mounjaro and Ozempic Used for the Same Thing?

Not necessarily. Approved indications depend on the exact product and country. Ozempic is a semaglutide product widely associated with type 2 diabetes treatment, while separate semaglutide products such as Wegovy are used for chronic weight management in markets where approved.

Tirzepatide is also marketed under different brand names and indications in different countries. For a patient in Thailand, the relevant question is not simply “Which drug is stronger?” but rather which registered product, indication and treatment pathway is medically appropriate for that individual.

What About Dosing?

Both medicines are generally administered once weekly, but their dose schedules are different. The milligram numbers should never be compared directly.

For example, 5 mg of tirzepatide is not equivalent to 1 mg, 2 mg or any other dose of semaglutide. They are different molecules with different dose ranges and titration schedules.

Starting dose, dose escalation and maintenance dose should be determined according to the specific medicine and medical guidance. Patients should not switch products or convert doses themselves.

Do They Have Similar Side Effects?

There is considerable overlap. Gastrointestinal effects are among the most commonly reported with both tirzepatide and semaglutide, particularly when treatment begins or the dose is increased.

Commonly discussed effects include:

• nausea;
• diarrhea;
• vomiting;
• constipation;
• reduced appetite;
• abdominal discomfort.

The direct head-to-head obesity trial reported that the most common adverse events in both groups were gastrointestinal and were mostly mild to moderate, occurring mainly during dose escalation.

More serious risks and contraindications also exist. A physician should review medical history, current medications and relevant warning signs before treatment and during follow-up.

Can You Switch From Ozempic to Mounjaro?

A patient may sometimes be considered for a different treatment, but switching is a medical decision rather than a simple dose conversion. The physician may need to consider the current medicine, dose, last injection date, treatment response, side effects, blood-sugar status, other medications and the reason for changing.

If you are already using Ozempic, Mounjaro, Wegovy or another related treatment, use ThailandSlim’s treatment-review pathway rather than starting over as a completely new patient.

Already Using Treatment → Start Treatment Review

Which One Is Better?

There is no single answer that applies to everyone.

Tirzepatide has produced greater average weight reduction than semaglutide in direct comparative clinical trials. However, “better” for an individual patient can also depend on:

• medical history and current health;
• type 2 diabetes or other metabolic conditions;
• previous treatment response;
• side effects and tolerability;
• other medications;
• contraindications and safety considerations;
• the product and indication that are appropriate and available;
• cost and continuity of treatment;
• physician judgment.

The stronger average result in one study does not remove the need for individual assessment.

Mounjaro and Ozempic in Thailand

Both Mounjaro (tirzepatide) and Ozempic (semaglutide) appear in Thailand’s official FDA drug-registration database. The database lists multiple registered strengths and presentations for both products.

Registration should not be confused with real-time availability, price or medical suitability. Stock, prescribing pathways and patient eligibility can vary.

For an overview of the options discussed on ThailandSlim, visit our Treatment Options page.

Frequently Asked Questions

Is Mounjaro the same as Ozempic?

No. Mounjaro contains tirzepatide, while Ozempic contains semaglutide. Tirzepatide activates GIP and GLP-1 receptors, while semaglutide activates GLP-1 receptors.

Is tirzepatide stronger than semaglutide?

Head-to-head trials have shown greater average weight reduction with tirzepatide in the studied populations. That does not mean it is automatically the best or safest option for every individual.

Can I compare the dose numbers directly?

No. Milligram doses of tirzepatide and semaglutide are not equivalent and should not be converted without medical guidance.

Can I use Ozempic or Mounjaro without a consultation?

Treatment suitability should be assessed by a qualified medical professional. ThailandSlim routes new patients through consultation before treatment is considered.

What if I already use one of these medicines?

Use the treatment-review pathway and provide your current or previous treatment, dose, timing, response and side-effect information.

Final Thoughts

Mounjaro and Ozempic share some similarities, but they are distinct medicines. Ozempic contains the GLP-1 receptor agonist semaglutide, while Mounjaro contains the dual GIP/GLP-1 receptor agonist tirzepatide.

Clinical research has shown meaningful differences in average weight reduction, but treatment choice should never be based on headline numbers alone. Safety, medical history, treatment goals, tolerability and continuity all matter.

For patients in Thailand who are new to treatment, the appropriate first step is an individual consultation rather than choosing a medicine from an online comparison.

Sources

Key factual references used for this article include the Thailand FDA National Drug Information database for registered Ozempic and Mounjaro products, and peer-reviewed head-to-head tirzepatide-versus-semaglutide trials published in the New England Journal of Medicine.

Medical Disclaimer